













TAU-Stanford-UCSF/Gladstone-Buck Institutes Symposium

Toward Personalized Diagnosis and Drug Screening

Celebrating the Taube-Koret Global Collaboration in Neurodegenerative Diseases

Sunday, Jan 12, 2020

Steinhardt Museum of Natural History, Tel Aviv University

	,,
9:00	Coffee
9:30	OPENING: Dean Abdussalam Azem, Karen B. Avraham, Uri Ashery, Harvey Cohen
9:45	Matthew Porteus, Stanford University Genetic engineering to create reagents to treat and understand Huntington's Disease
10:30	Miguel Weil, Tel Aviv University Establishment of a personalized diagnosis and drug screening system for patients with Huntington's disease
11:00	Uri Ashery , Tel Aviv University Identifying alpha-synuclein aggregation using super-resolution microscopy: challenges and future directions
11:30	Frank Longo, Stanford University Small molecule modulation of neurodegenerative signaling in Huntington's Disease: Morphological-behavioral-biomarker outcomes
12:15	Light lunch
13:00	ROUNDTABLE: What pieces are we missing to cure Huntington's Disease?
	Moderated by Dean Ehud Grossman
13:15	Hagit Eldar-Finkelman, Tel Aviv University
	Discovery and design of novel GSK-3 inhibitors for treating neurodegenerative disorders
13:45	Steve Finkbeiner , UCSF-Gladstone Institutes Finding therapeutic targets and treatments for neurodegenerative disease with patient-derived stem cells, robotics and artificial intelligence
14:30	Dan Frenkel , Tel Aviv University Targeting the role of astrocytes cellular senescence in the progression of neurodegenerative diseases
15:00	Lisa Ellerby, Buck Institute
	Modeling Huntington's Disease with induced pluripotent stem cells
15:45	Avi Ashkenazi, Tel Aviv University
16:15	Identifying modulators of alpha synuclein levels and toxicity via ubiquitin signaling Blavatnik Drug Discovery Center Tour